Risk Models to Predict Hypertension: A Systematic Review

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Echouffo Tcheugui, Justin B ^a   Batty, G David ^b   Kivimäki, Mika ^b   Kengne, Andre P ^c,d,e  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BLOOD PRESSURE; BODY MASS; CALIBRATION; CLINICAL ARTICLE; DIABETES MELLITUS; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HYPERTENSION; MALE; PREDICTION; QUALITY CONTROL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VALIDATION PROCESS;

ALGORITHMS; HUMANS; HYPERTENSION; MODELS, STATISTICAL; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84879832416     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067370     Document Type: Review

References (37)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, et al. (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365: 217-223.
2. Lawes CM, Vander Hoorn S, Rodgers A, (2008) Global burden of blood-pressure-related disease, 2001. Lancet 371: 1513-1518.
3. Mendis S, Puska P, Norrving B, editors (2011) Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, Geneva.
4. Greenlund KJ, Croft JB, Mensah GA, (2004) Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch Intern Med 164: 2113-2118.
5. Wang Y, Wang QJ, (2004) The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 164: 2126-2134.
6. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, et al. (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 287: 1003-1010.
7. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D, (2001) Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 358: 1682-1686.
8. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, et al. (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354: 1685-1697.
9. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ, (2000) Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 35: 544-549.
10. The Trials of Hypertension Prevention Collaborative Research Group (1997) Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 157: 657-667.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572.
12. Juni P, Altman DG, Egger M, (2001) Systematic reviews in health care: Assessing the quality of controlled clinical trials. Bmj 323: 42-46.
13. Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, et al. (2012) Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart.
14. Moons KG, Kengne AP, Grobbee DE, Royston P, Vergouwe Y, et al. (2012) Risk prediction models: II. External validation, model updating, and impact assessment. Heart.
15. Parikh NI, Pencina MJ, Wang TJ, Benjamin EJ, Lanier KJ, et al. (2008) A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med 148: 102-110.
16. Reilly BM, Evans AT, (2006) Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Annals of internal medicine 144: 201-209.
17. Pearson TA, LaCroix AZ, Mead LA, Liang KY, (1990) The prediction of midlife coronary heart disease and hypertension in young adults: the Johns Hopkins multiple risk equations. Am J Prev Med 6: 23-28.
18. Paynter NP, Cook NR, Everett BM, Sesso HD, Buring JE, et al. (2009) Prediction of incident hypertension risk in women with currently normal blood pressure. Am J Med 122: 464-471.
19. Kshirsagar AV, Chiu YL, Bomback AS, August PA, Viera AJ, et al. (2010) A hypertension risk score for middle-aged and older adults. J Clin Hypertens (Greenwich) 12: 800-808.
20. Kivimaki M, Batty GD, Singh-Manoux A, Ferrie JE, Tabak AG, et al. (2009) Validating the Framingham Hypertension Risk Score: results from the Whitehall II study. Hypertension 54: 496-501.
21. Kivimaki M, Tabak AG, Batty GD, Ferrie JE, Nabi H, et al. (2010) Incremental predictive value of adding past blood pressure measurements to the Framingham hypertension risk equation: the Whitehall II Study. Hypertension 55: 1058-1062.
22. Fava C, Sjogren M, Montagnana M, Danese E, Almgren P, et al. (2013) Prediction of blood pressure changes over time and incidence of hypertension by a genetic risk score in Swedes. Hypertension 61: 319-326.
23. Bozorgmanesh M, Hadaegh F, Mehrabi Y, Azizi F, (2011) A point-score system superior to blood pressure measures alone for predicting incident hypertension: Tehran Lipid and Glucose Study. J Hypertens 29: 1486-1493.
24. Chien KL, Hsu HC, Su TC, Chang WT, Sung FC, et al. (2011) Prediction models for the risk of new-onset hypertension in ethnic Chinese in Taiwan. J Hum Hypertens 25: 294-303.
25. Lim NK, Son KH, Lee KS, Park HY, Cho MC, (2013) Predicting the risk of incident hypertension in a korean middle-aged population: korean genome and epidemiology study. J Clin Hypertens (Greenwich) 15: 344-349.
26. Muntner P, Woodward M, Mann DM, Shimbo D, Michos ED, et al. (2010) Comparison of the Framingham Heart Study hypertension model with blood pressure alone in the prediction of risk of hypertension: the Multi-Ethnic Study of Atherosclerosis. Hypertension 55: 1339-1345.
27. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK, (1996) The progression from hypertension to congestive heart failure. JAMA 275: 1557-1562.
28. Franco OH, Peeters A, Bonneux L, de Laet C, (2005) Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension 46: 280-286.
29. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 44: 720-732.
30. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421.
31. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117: 743-753.
32. Anderson KM, Odell PM, Wilson PW, Kannel WB, (1991) Cardiovascular disease risk profiles. Am Heart J 121: 293-298.
33. van Dieren S, Beulens JW, Kengne AP, Peelen LM, Rutten GE, et al. (2012) Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 98: 360-369.
34. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, et al. (2011) A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305: 1553-1559.
35. Dhingra R, Pencina MJ, Schrader P, Wang TJ, Levy D, et al. (2009) Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community. Circulation 119: 1101-1107.
36. Wang TJ, Gona P, Larson MG, Levy D, Benjamin EJ, et al. (2007) Multiple biomarkers and the risk of incident hypertension. Hypertension 49: 432-438.
37. Kraja AT, Hunt SC, Rao DC, Davila-Roman VG, Arnett DK, et al. (2011) Genetics of hypertension and cardiovascular disease and their interconnected pathways: lessons from large studies. Curr Hypertens Rep 13: 46-54.